183 related articles for article (PubMed ID: 16533784)
1. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
4. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Tawbi HA; Villaruz L; Tarhini A; Moschos S; Sulecki M; Viverette F; Shipe-Spotloe J; Radkowski R; Kirkwood JM
Br J Cancer; 2011 Sep; 105(6):773-7. PubMed ID: 21811257
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Sabharwal A; Corrie PG; Midgley RS; Palmer C; Brady J; Mortimer P; Watson AJ; Margison GP; Middleton MR
Cancer Chemother Pharmacol; 2010 Oct; 66(5):829-35. PubMed ID: 20039040
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Quinn JA; Desjardins A; Weingart J; Brem H; Dolan ME; Delaney SM; Vredenburgh J; Rich J; Friedman AH; Reardon DA; Sampson JH; Pegg AE; Moschel RC; Birch R; McLendon RE; Provenzale JM; Gururangan S; Dancey JE; Maxwell J; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2005 Oct; 23(28):7178-87. PubMed ID: 16192602
[TBL] [Abstract][Full Text] [Related]
9. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
[TBL] [Abstract][Full Text] [Related]
12. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Lee SM; Thatcher N; Crowther D; Margison GP
Br J Cancer; 1994 Mar; 69(3):452-6. PubMed ID: 8123472
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
[TBL] [Abstract][Full Text] [Related]
15. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
16. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
17. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Middleton MR; Kelly J; Thatcher N; Donnelly DJ; McElhinney RS; McMurry TB; McCormick JE; Margison GP
Int J Cancer; 2000 Jan; 85(2):248-52. PubMed ID: 10629085
[TBL] [Abstract][Full Text] [Related]
18. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
[TBL] [Abstract][Full Text] [Related]
19. Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Caporaso P; Turriziani M; Venditti A; Marchesi F; Buccisano F; Tirindelli MC; Alvino E; Garbin A; Tortorelli G; Toppo L; Bonmassar E; D'Atri S; Amadori S
DNA Repair (Amst); 2007 Aug; 6(8):1179-86. PubMed ID: 17500047
[TBL] [Abstract][Full Text] [Related]
20. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Geoerger B; Vassal G; Doz F; O'Quigley J; Wartelle M; Watson AJ; Raquin MA; Frappaz D; Chastagner P; Gentet JC; Rubie H; Couanet D; Geoffray A; Djafari L; Margison GP; Pein F
Br J Cancer; 2005 Sep; 93(5):529-37. PubMed ID: 16136028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
